ACS Medicinal Chemistry Letters
Letter
(11) Li, Y.; Guo, B.; Xu, Z.; Li, B.; Cai, T.; Zhang, X.; Yu, Y.; Wang,
H.; Shi, J.; Zhu, W. Repositioning organohalogen drugs: a case study
for identification of potent B-Raf V600E inhibitors via docking and
bioassay. Sci. Rep. 2016, 6, 31074.
(12) Zhou, Y.; Ma, J.; Lin, X.; Huang, X. P.; Wu, K.; Huang, N.
Structure-based discovery of novel and selective 5-hydroxytryptamine
2B receptor antagonists for the treatment of irritable bowel syndrome.
J. Med. Chem. 2016, 59, 707−720.
(13) Politzer, P.; Lane, P.; Concha, M. C.; Ma, Y.; Murray, J. S. An
overview of halogen bonding. J. Mol. Model. 2007, 13, 305−311.
(14) Ibrahim, M. A. Molecular mechanical study of halogen bonding
in drug discovery. J. Comput. Chem. 2011, 32, 2564−2574.
(15) Lu, Y.; Wang, Y.; Zhu, W. Nonbonding interactions of organic
halogens in biological systems: implications for drug discovery and
biomolecular design. Phys. Chem. Chem. Phys. 2010, 12, 4543−4551.
(16) Schiff, P. L. Ergot and its alkaloids. Am. J. Pharm. Educ. 2006,
70, 98.
(29) Lin, F.-Y.; MacKerell, A. D., Jr Do Halogen−Hydrogen Bond
Donor Interactions Dominate the Favorable Contribution of
Halogens to Ligand−Protein Binding? J. Phys. Chem. B 2017, 121,
6813−6821.
(30) Cusack, B.; Nelson, A.; Richelson, E. Binding of antidepressants
to human brain receptors: focus on newer generation compounds.
Psychopharmacology 1994, 114, 559−565.
(31) Kulak-Bejda, A.; Bejda, G.; Waszkiewicz, N. Antidepressants for
irritable bowel syndrome-A systematic review. Pharmacol. Rep. 2017,
69, 1366−1379.
(32) Wouters, M. M.; Roeder, J. L.; Tharayil, V. S.; Stanich, J. E.;
Strege, P. R.; Lei, S.; Bardsley, M. R.; Ordog, T.; Gibbons, S. J.;
Farrugia, G. Protein kinase Cγ mediates regulation of proliferation by
the serotonin 5-hydroxytryptamine receptor 2B. J. Biol. Chem. 2009,
284, 21177−21184.
(17) Wacker, D.; Wang, C.; Katritch, V.; Han, G. W.; Huang, X. P.;
Vardy, E.; McCorvy, J. D.; Jiang, Y.; Chu, M.; Siu, F.; et al. Structural
features for functional selectivity at serotonin receptors. Science 2013,
340, 615−619.
(18) Wacker, D.; Wang, S.; McCorvy, J. D.; Betz, R. M.;
Venkatakrishnan, A. J.; Levit, A.; Lansu, K.; Schools, Z. L.; Che, T.;
Nichols, D. E.; Shoichet, B. K.; Dror, R. O.; Roth, B. L. Crystal
structure of an LSD-bound human serotonin receptor. Cell 2017, 168,
377−389 e312.
(19) Shimamura, T.; Shiroishi, M.; Weyand, S.; Tsujimoto, H.;
Winter, G.; Katritch, V.; Abagyan, R.; Cherezov, V.; Liu, W.; Han, G.
W.; Kobayashi, T.; Stevens, R. C.; Iwata, S. Structure of the human
histamine H1 receptor complex with doxepin. Nature 2011, 475, 65−
70.
(20) Poissonnet, G.; Parmentier, J. G.; Boutin, J. A.; Goldstein, S.
The emergence of selective 5-HT2B antagonists structures, activities
and potential therapeutic applications. Mini-Rev. Med. Chem. 2004, 4,
325−330.
(21) Brea, J.; Castro-Palomino, J.; Yeste, S.; Cubero, E.; Parraga, A.;
Dominguez, E.; Loza, M. I. Emerging opportunities and concerns for
drug discovery at serotonin 5-HT2B receptors. Curr. Top. Med. Chem.
2010, 10, 493−503.
(22) Voth, A. R.; Khuu, P.; Oishi, K.; Ho, P. S. Halogen bonds as
orthogonal molecular interactions to hydrogen bonds. Nat. Chem.
2009, 1, 74−79.
(23) Fujita, W.; Gomes, I.; Dove, L. S.; Prohaska, D.; McIntyre, G.;
Devi, L. A. Molecular characterization of eluxadoline as a potential
ligand targeting mu-delta opioid receptor heteromers. Biochem.
Pharmacol. 2014, 92, 448−456.
(24) Borman, R. A.; Tilford, N. S.; Harmer, D. W.; Day, N.; Ellis, E.
S.; Sheldrick, R. L.; Carey, J.; Coleman, R. A.; Baxter, G. S. 5-HT(2B)
receptors play a key role in mediating the excitatory effects of 5-HT in
human colon in vitro. Br. J. Pharmacol. 2002, 135, 1144−1151.
(25) Bassil, A. K.; Taylor, C. M.; Bolton, V. J. N.; Gray, K. M.;
Brown, J. D.; Cutler, L.; Summerfield, S. G.; Bruton, G.; Winchester,
W. J.; Lee, K.; Sanger, G. J. Inhibition of colonic motility and
defecation by RS-127445 suggests an involvement of the 5-HT2B
receptor in rodent large bowel physiology. Br. J. Pharmacol. 2009, 158,
252−258.
(26) Takahashi, N.; Inagaki, K.; Taniguchi, K.; Sakaguchi, Y.;
Kawamura, K. The novel 5-HT2B receptor antagonist, RQ-00310941,
attenuates visceral hypersensitivity and abnormal defecation in rat
models. Gastroenterology 2011, 140, S-607.
(27) Kapadia, N.; Ahmed, S.; Harding, W. W. New halogenated tris-
(phenylalkyl) amines as h5-HT2B receptor ligands. Bioorg. Med.
Chem. Lett. 2016, 26, 3216−3219.
́
(28) Gonzalez-Vera, J. A.; Medina, R. A.; Martín-Fontecha, M.;
́
́
Gonzalez, A.; de La Fuente, T.; Vazquez-Villa, H.; García-Carceles, J.;
́
Botta, J.; McCormick, P. J.; Benhamu, B.; Pardo, L.; Lopez-Rodriguez,
M. L. A new serotonin 5-HT 6 receptor antagonist with procognitive
activity−Importance of a halogen bond interaction to stabilize the
binding. Sci. Rep. 2017, 7, 41293.
F
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX